Population pharmacokinetics of pranlukast hydrate dry syrup in children with bronchial asthma

Allergology International

Volumn 52, Issue 4, 2003, Pages 213-218

  Inoue, Ryosuke ^a   Teramoto, Takahide ^a   Nakade, Susumu ^b,d   Okamoto, Hiroyuki ^b   Yukawa, Eiji ^c   Higuchi, Shun ^d   Kondo, Naomi ^a   Mikawa, Haruki ^e  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e Kansai Denryoku Hospital   (Japan)

Author keywords

Children with bronchial asthma; Population pharmacokinetics; Pranlukast

Indexed keywords

PRANLUKAST;

ADOLESCENT; ARTICLE; ASTHMA; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; HUMAN; PRIORITY JOURNAL; SYRUP;

EID: 0347985058     PISSN: 13238930     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1323-8930.2003.00304.x     Document Type: Article

References (15)

1. Obata T, Okada Y, Motoishi M et al. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn. J. Pharmacol. 1992; 60: 227-37.
2. Sukou M, Okudaira H, Ito K. Leukotriene C4, D4, E4 antagonist (ONO-1078) on immediate and late asthmatic response induced by antigen inhalation. J. Clin. Ther. Med. 1993; 9: 221-4.
3. 2 synthetase inhibitor on antigen-induced bronchoconstriction in patients with asthma. Chest 1998; 114: 1028-32.
4. Hamilton A, Faiferman I, Stober P et al. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J. Allergy Clin. Immunol. 1998; 102: 170-2.
5. Fujimura M, Sakamoto S, Kamio Y et al. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir. Med. 1993; 87: 133-8.
6. Nakamura Y, Hoshino M, Sim JJ etal. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax 1998; 53: 835-41.
7. Hisada T, Salmon M, Nasuhara Y et al. Cysteinyl-leukotrienes partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5 transgenic mice. Am. J. Respir. Crit. Care Med. 1999; 160: 571-5.
8. Hirata K, Kurihara N, Kamimori T et al. Exercise-induced asthma and leukotriene receptor antagonist. J. Clin. Ther. Med. 1993; 9: 225-8.
9. Ette EI. Stability and performance of a population pharmacokinetics model. J. Clin. Pharmacol. 1997; 37: 486-95.
10. Parke J, Charles BG. Factors affecting oral cyclosporin disposition after heart transplantation: Bootstrap validation of a population pharmacokinetic model. Eur. J. Clin. Pharmacol. 2000; 56: 481-7.
11. Takama H, Tanaka H, Sudo T et al. Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study. Cancer Chemother. Pharmacol. 2001; 47: 404-10.
12. McFadyen ML, Miller R, Ludden TM. Ketotifen pharmacokinetics in children with atopic perennial asthma. Eur. J. Clin. Pharmacol. 1997; 52: 383-6.
13. Yukawa E, To H, Ohdo S et al. Detection of a drug-drug interaction on population-based phenobarbitone clearance using nonlinear mixed-effects modeling. Eur. J. Clin. Pharmacol. 1998; 54: 69-74.
14. Yukawa E, Aoyama T. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J. Clin. Pharmacol. 1996; 36: 752-9.
15. Rylance GW, Moreland TA, Cowan MD et al. Liver volume estimation using ultrasound scanning. Arch. Dis. Child. 1982; 57: 283-6.